Clinical Trials Browser

Phase 2 × Immunoglobulin Light-chain Amyloidosis × elotuzumab × Clear all

NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Phase 2 Unknown

Immunoglobulin Light-chain Amyloidosis